Russell Investments Group
STRO icon

Russell Investments Group’s Sutro Biopharma STRO Stock Holding History

Russell Investments Group’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.3K Buy
+1,275
New +$39.8K ﹤0.01% 3660
2025
Q2 		– Sell
-926
Closed -$6.02K – 3950
2025
Q1 		$6.02K Sell
926
-9,019
-91% -$142K ﹤0.01% 3316
2024
Q4 		$183K Sell
9,945
-5,177
-34% -$158K ﹤0.01% 2560
2024
Q3 		$523K Buy
15,122
+2,299
+18% +$90.1K ﹤0.01% 2263
2024
Q2 		$376K Buy
12,823
+1,627
+15% +$64.3K ﹤0.01% 2302
2024
Q1 		$633K Buy
11,196
+7,374
+193% +$326K ﹤0.01% 2138
2023
Q4 		$164K Sell
3,822
-7,038
-65% -$223K ﹤0.01% 2470
2023
Q3 		$377K Sell
10,860
-2,820
-21% -$123K ﹤0.01% 2323
2023
Q2 		$636K Sell
13,680
-303
-2% -$15.1K ﹤0.01% 2141
2023
Q1 		$646K Buy
13,983
+3,087
+28% +$196K ﹤0.01% 2163
2022
Q4 		$880K Sell
10,896
-30
-0.3% -$2.08K ﹤0.01% 2039
2022
Q3 		$604K Sell
10,926
-2,120
-16% -$125K ﹤0.01% 2166
2022
Q2 		$678K Buy
13,046
+8,028
+160% +$448K ﹤0.01% 2133
2022
Q1 		$410K Buy
5,018
+3,281
+189% +$312K ﹤0.01% 2285
2021
Q4 		$258K Hold
1,737
– – ﹤0.01% 2651
2021
Q3 		$328K Hold
1,737
– – ﹤0.01% 2620
2021
Q2 		$322K Sell
1,737
-3,816
-69% -$747K ﹤0.01% 2754
2021
Q1 		$1.26M Buy
5,553
+430
+8% +$102K ﹤0.01% 2139
2020
Q4 		$1.11M Buy
5,123
+2,334
+84% +$386K ﹤0.01% 2073
2020
Q3 		$278K Buy
2,789
+1,696
+155% +$160K ﹤0.01% 2641
2020
Q2 		$84K Sell
1,093
-29
-3% -$2.78K ﹤0.01% 2919
2020
Q1 		$113K Buy
1,122
+36
+3% +$3.78K ﹤0.01% 2698
2019
Q4 		$118K Buy
+1,086
New +$112K ﹤0.01% 2846

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Russell Investments Group's STRO Position: Q2 2026 in Review

Russell Investments Group opened a new position in Sutro Biopharma (STRO) in Q2 2026: 1,275 shares worth $42.3K. The stake represents ﹤0.01% of the portfolio and ranks #3660 among its holdings. This is a return to the name: Russell Investments Group previously reported a position in STRO as recently as Q1 2025.

Russell Investments Group first reported a position in STRO in Q4 2019 and has held it in 23 quarters since. The position peaked at $1.26M in Q1 2021. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Russell Investments Group held 1,275 shares of Sutro Biopharma worth $42.3K as of Q2 2026.
  • Sutro Biopharma was a new Russell Investments Group position in Q2 2026.
  • Sutro Biopharma made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3660 holding.
  • Russell Investments Group first reported a position in Sutro Biopharma in Q4 2019 and has held it in 23 quarters since.
  • Russell Investments Group's Sutro Biopharma position peaked at $1.26M in Q1 2021.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.